Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.
Website: ientra.com



Growth: Bad revenue growth rate -13.0%, there is slowdown compared to average historical growth rates 11.1%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -49.5%. On average the margin is improving steadily. Gross margin is high, +51.3%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 20% of quarters (showing a gain of -$0.43 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 640.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 0.0% higher than minimum and 99.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -0.7x by EV / Sales multiple

Key Financials (Download financials)

Ticker: SIEN
Share price, USD:  (0.0%)0.174
year average price 1.4647  


year start price 1.4800 2023-05-06

max close price 4.5500 2023-07-19

min close price 0.1740 2024-02-21

current price 0.1740 2024-05-04
Common stocks: 6 284 817

Dividend Yield:  0.0%
Last revenue growth (y/y):  -13.0%
Last growth of EBITDA (y/y):  ---
Historical revenue growth:  11.1%
Historical growth of EBITDA:  5.4%
EV / Sales: 0.6x
Margin (EBITDA LTM / Revenue): -49.5%
Fundamental value created in LTM:
Market Cap ($m): 1
Net Debt ($m): 51
EV (Enterprise Value): 52
Price to Book: -0.0x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2023-11-09Seeking Alpha

Sientra, Inc. (SIEN) Q3 2023 Earnings Call Transcript

2023-11-08GlobeNewsWire

Sientra to Present at the Stifel 2023 Healthcare Conference

2023-08-10Zacks Investment Research

Sientra (SIEN) Reports Q2 Loss, Lags Revenue Estimates

2023-07-27GlobeNewsWire

Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023

2023-06-1524/7 Wall Street

As Sientra Options Become Less Bullish This Week, Short Sellers Are Moving In

2023-06-05Zacks Investment Research

Why Fast-paced Mover Sientra (SIEN) Is a Great Choice for Value Investors

2023-05-18Zacks Investment Research

Despite Fast-paced Momentum, Sientra (SIEN) Is Still a Bargain Stock

2023-05-11Seeking Alpha

Sientra, Inc. (SIEN) Q1 2023 Earnings Call Transcript

2023-05-01GlobeNewsWire

Sientra to Report First Quarter 2023 Financial Results on May 11, 2023
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol SIEN SIEN SIEN SIEN SIEN SIEN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-13 2023-08-11 2023-05-15 2023-04-18 2022-11-14 2022-08-11
acceptedDate 2023-11-13 16:52:15 2023-08-11 17:07:26 2023-05-12 17:53:11 2023-04-17 17:35:26 2022-11-14 17:21:11 2022-08-11 16:17:16
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
revenue 20M 23M 23M 25M 23M 22M
costOfRevenue 10M 11M 10M 22M 10M 9M
grossProfit 10M 13M 12M 3M 13M 13M
grossProfitRatio 0.513 0.545 0.539 0.129 0.566 0.592
researchAndDevelopmentExpenses 2M 2M 3M 4M 4M 3M
generalAndAdministrativeExpenses 8M 7M 10M 10M 9M 12M
sellingAndMarketingExpenses 9M 10M 10M 14M 12M 14M
sellingGeneralAndAdministrativeExpenses 17M 17M 20M 23M 22M 26M
otherExpenses -24 000 -44 000 -57 000 221 000 0 0
operatingExpenses 19M 20M 23M 28M 25M 29M
costAndExpenses 29M 30M 33M 50M 35M 37M
interestIncome 168 000 184 000 106 000 72 000 41 000 15 000
interestExpense 2M 3M 2M 3M 2M 2M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M
ebitda -7M -5M -9M -22M -11M -14M
ebitdaratio -0.378 -0.222 -0.384 -0.897 -0.486 -0.663
operatingIncome -9M -7M -11M -24M -13M -16M
operatingIncomeRatio -0.481 -0.307 -0.468 -0.976 -0.556 -0.741
totalOtherIncomeExpensesNet -3M -44 000 -2M 2M -2M -2M
incomeBeforeTax -15M -9M -13M -22M -15M -18M
incomeBeforeTaxRatio -0.756 -0.410 -0.572 -0.892 -0.660 -0.848
incomeTaxExpense 2M 2M 5M 27 000 94 000 58 000
netIncome -15M -9M -18M -22M -15M -18M
netIncomeRatio -0.756 -0.410 -0.780 -0.893 -0.664 -0.851
eps -1.310 -0.850 -1.440 -2.350 -2.380 -2.922
epsdiluted -1.310 -0.850 -1.440 -2.350 -2.380 -2.922
weightedAverageShsOut 11M 11M 12M 10M 6M 6M
weightedAverageShsOutDil 11M 11M 12M 10M 6M 6M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Balance Sheet Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol SIEN SIEN SIEN SIEN SIEN SIEN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-13 2023-08-11 2023-05-15 2023-04-18 2022-11-14 2022-08-11
acceptedDate 2023-11-13 16:52:15 2023-08-11 17:07:26 2023-05-12 17:53:11 2023-04-17 17:35:26 2022-11-14 17:21:11 2022-08-11 16:17:16
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
cashAndCashEquivalents 15M 19M 19M 26M 19M 25M
shortTermInvestments 0 0 0 0 0 0
cashAndShortTermInvestments 15M 19M 19M 26M 19M 25M
netReceivables 30M 32M 36M 37M 34M 36M
inventory 39M 39M 41M 43M 52M 53M
otherCurrentAssets 3M 2M 1M 2M 4M 4M
totalCurrentAssets 87M 92M 97M 108M 109M 118M
propertyPlantEquipmentNet 19M 20M 21M 22M 21M 20M
goodwill 9M 9M 9M 9M 9M 9M
intangibleAssets 24M 24M 25M 26M 26M 27M
goodwillAndIntangibleAssets 34M 33M 34M 35M 36M 36M
longTermInvestments 606 000 606 000 0 0 0 0
taxAssets -606 000 -606 000 0 0 0 0
otherNonCurrentAssets 849 000 849 000 849 000 849 000 881 000 894 000
totalNonCurrentAssets 53M 54M 56M 58M 57M 57M
otherAssets 0 0 0 0 0 0
totalAssets 140M 146M 153M 165M 166M 175M
accountPayables 5M 5M 5M 7M 7M 7M
shortTermDebt 59M 2M 2M 2M 2M 10M
taxPayables 0 0 0 0 0 0
deferredRevenue 54M 54M 50M 45M 43M 38M
otherCurrentLiabilities 34M 28M 31M 36M 29M 29M
totalCurrentLiabilities 152M 88M 88M 90M 81M 84M
longTermDebt 4M 62M 62M 61M 77M 71M
deferredRevenueNonCurrent 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0
otherNonCurrentLiabilities 16M 14M 13M 15M 37M 12M
totalNonCurrentLiabilities 20M 76M 75M 77M 89M 82M
otherLiabilities 0 0 0 0 0 0
capitalLeaseObligations 4M 4M 5M 6M 9M 9M
totalLiabilities 172M 165M 164M 166M 170M 167M
preferredStock 0 0 0 0 0 0
commonStock 114 000 113 000 112 000 107 000 630 000 627 000
retainedEarnings -732M -717M -708M -695M -673M -658M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0
othertotalStockholdersEquity 700M 698M 697M 694M 668M 666M
totalStockholdersEquity -32M -19M -10M -822 000 -4M 9M
totalEquity -32M -19M -10M -822 000 -4M 9M
totalLiabilitiesAndStockholdersEquity 140M 146M 153M 165M 166M 175M
minorityInterest 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 140M 146M 153M 165M 166M 175M
totalInvestments 606 000 606 000 0 0 0 0
totalDebt 63M 62M 62M 63M 79M 81M
netDebt 48M 44M 42M 37M 60M 56M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Cash Flow Statement

Property 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2022 q2
date 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30
symbol SIEN SIEN SIEN SIEN SIEN SIEN
reportedCurrency USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M
fillingDate 2023-11-13 2023-08-11 2023-05-15 2023-04-18 2022-11-14 2022-08-11
acceptedDate 2023-11-13 16:52:15 2023-08-11 17:07:26 2023-05-12 17:53:11 2023-04-17 17:35:26 2022-11-14 17:21:11 2022-08-11 16:17:16
calendarYear 2023.000 2023.000 2023.000 2022.000 2022.000 2022.000
period Q3 Q2 Q1 Q4 Q3 Q2
netIncome -15M -9M -13M -23M -15M -18M
depreciationAndAmortization 2M 2M 2M 2M 2M 2M
deferredIncomeTax 4M 480 000 0 0 0 0
stockBasedCompensation 1M 1M 2M 2M 2M 2M
changeInWorkingCapital 3M 4M 541 000 9M 7M -255 000
accountsReceivables 2M 4M 639 000 -3M 1M 3M
inventory 80 000 1M 2M 4M 958 000 962 000
accountsPayables 1M -2M -7M 3M -823 000 -3M
otherWorkingCapital -120 000 515 000 5M 5M 5M 3M
otherNonCashItems 1M 1M 3M 9M 2M 2M
netCashProvidedByOperatingActivities -3M -525 000 -6M -2M -3M -13M
investmentsInPropertyPlantAndEquipment -270 000 -168 000 -618 000 -2M -1M -567 000
acquisitionsNet 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0
otherInvestingActivites 0 0 0 0 0 0
netCashUsedForInvestingActivites -270 000 -168 000 -618 000 -2M -1M -567 000
debtRepayment 0 0 0 -21M -2M -3M
commonStockIssued 175 000 -3000.000 256 000 14M 0 0
commonStockRepurchased 166 000 475 000 0 0 0 0
dividendsPaid 0 0 0 0 0 0
otherFinancingActivites -316 000 -498 000 -85 000 18M 128 000 2M
netCashUsedProvidedByFinancingActivities 25 000 -26 000 171 000 10M -2M -282 000
effectOfForexChangesOnCash 0 0 0 -2000.000 0 0
netChangeInCash -4M -719 000 -7M 7M -6M -14M
cashAtEndOfPeriod 16M 19M 20M 26M 19M 25M
cashAtBeginningOfPeriod 19M 20M 27M 19M 25M 39M
operatingCashFlow -3M -525 000 -6M -2M -3M -13M
capitalExpenditure -270 000 -168 000 -618 000 -2M -1M -567 000
freeCashFlow -4M -693 000 -7M -3M -4M -14M
link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link

Earning call transcript

2023 q3
2023-11-09 ET (fiscal 2023 q3)
2023 q2
2023-08-10 ET (fiscal 2023 q2)
2023 q1
2023-05-11 ET (fiscal 2023 q1)
2022 q4
2023-03-30 ET (fiscal 2022 q4)
2022 q3
2022-11-10 ET (fiscal 2022 q3)
2022 q2
2022-08-11 ET (fiscal 2022 q2)
2022 q1
2022-05-12 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-02-13 13:30 ET
Sientra to Pursue Strategic Sale of its Business Through Voluntary Chapter 11 Process
2023-11-09 21:05 ET
Sientra Reports Third Quarter Financial and Operational Results
2023-11-08 13:35 ET
Sientra to Present at the Stifel 2023 Healthcare Conference
2023-10-30 21:00 ET
Sientra Reports Preliminary Unaudited Third Quarter 2023 Financial Results and Provides Update on Outlook
2023-08-10 20:03 ET
Sientra Reports Record Second Quarter Financial and Operational Results
2023-07-27 08:05 ET
Sientra to Report Second Quarter 2023 Financial Results on August 10, 2023
2023-06-20 12:35 ET
Sientra Announces Appointment of Alexander W. Casdin to Board of Directors
2023-06-08 20:05 ET
Sientra Announces FDA-Clearance of Next Generation AlloX2 Pro™ Tissue Expander
2023-05-17 12:30 ET
Sientra Announces FDA-Clearance of Novel Portfinder™ Technology
2023-05-11 20:02 ET
Sientra Reports Record First Quarter 2023 Operational Results
2023-05-01 20:05 ET
Sientra to Report First Quarter 2023 Financial Results on May 11, 2023
2023-03-30 20:02 ET
Sientra Reports Record Fourth Quarter and Full Year Revenues and Expands Total Addressable Market With New Product Launches
2023-03-22 12:30 ET
Aziyo Biologics and Sientra Announce SimpliDerm® Partnership to Improve Women’s Access to Biologics for Soft Tissue Reconstruction
2023-03-20 12:35 ET
Sientra to Report Fourth Quarter and Full Year 2022 Financial Results on March 30, 2023
2023-03-01 13:32 ET
Sientra Announces Preliminary Results from Clinical Study and The First Shipment of Viality™ Fat Transfer System
2023-01-20 14:25 ET
Sientra Announces 1-for-10 Reverse Stock Split
2022-12-29 21:05 ET
Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-12-13 21:05 ET
Sientra Expands Global Footprint With Regulatory Approval to Market Breast Implants in the United Arab Emirates
2022-11-10 21:05 ET
Sientra Reports Record Third Quarter 2022 Financial Results
2022-10-31 20:05 ET
Sientra to Report Third Quarter 2022 Financial Results on November 10, 2022
2022-10-21 11:30 ET
Sientra Announces Pricing of $13.2 Million Public Offering
2022-10-18 22:08 ET
Sientra Announces Proposed Public Offering
2022-10-12 12:45 ET
Sientra Announces Preliminary Unaudited Third Quarter Financial Results and Signing of Senior Secured Loan Facilities With Deerfield Management
2022-10-03 12:45 ET
Sientra Supports Breast Cancer Awareness Month by Launching Educational Programs Designed to Empower Women
2022-09-20 12:00 ET
Sientra Receives Regulatory Approval to Market Breast Implants in Saudi Arabia
2022-09-06 20:30 ET
Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2022-08-11 20:05 ET
Sientra Reports Second Quarter Revenue Growth Driven By Increased Acceleration in Reconstruction Channel
2022-07-28 12:30 ET
Sientra to Report Second Quarter 2022 Financial Results on August 11, 2022
2022-07-11 13:00 ET
Sientra Wins Premier’s Horizon Award for 2022 for Exceptional Customer Service, Engagement, and Value Creation
2022-07-06 13:00 ET
FDA Approves Sientra’s Low Plus Profile Projection Breast Implant
2022-05-23 13:00 ET
Sientra To Present At The William Blair 42nd Annual Growth Stock Conference
2022-05-18 20:30 ET
Sientra To Participate At The 19th Annual Craig-Hallum Institutional Investor Conference
2022-05-12 20:05 ET
Sientra Reports Seventh Consecutive Quarter of Record Growth for First Quarter 2022
2022-05-03 21:30 ET
Sientra to Report First Quarter 2022 Financial Results on May 12, 2022
2022-03-24 20:15 ET
Sientra to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT
2022-03-24 12:00 ET
Sientra Receives Regulatory Approval to Market Breast Implants in Canada
2022-03-23 20:10 ET
Sientra Reports Record Plastic Surgery Revenue for Both Fourth Quarter and Full Year 2021
2022-03-09 21:05 ET
Sientra to Report Fourth Quarter and Full Year 2021 Financial Results on March 23, 2022
2022-01-10 13:00 ET
Sientra Reports Record Preliminary Unaudited Fourth Quarter and Full Year 2021 Revenues
2022-01-05 13:00 ET
Sientra Announces Acquisition of Novel Fat Grafting Technology from AuraGen Aesthetics, LLC
2021-12-27 21:01 ET
Sientra to Present at the H.C. Wainwright Bioconnect Virtual Conference
2021-12-02 21:05 ET
Sientra Selects Leading Distributors for Two Key International Markets In Preparation for Further Expansion and Growth Acceleration
2021-11-10 21:01 ET
Sientra Reports Record Third Quarter 2021 Revenue for Continuing Operations
2021-11-01 20:05 ET
Sientra to Participate in Upcoming Investor Conferences
2021-10-27 20:01 ET
Sientra to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021
2021-10-19 20:35 ET
Sientra® And Mission Plasticos Launch Reshaping Lives: Full Circle™ A Philanthropic Initiative For Women Living In Poverty In America
2021-08-25 12:00 ET
New Study Confirms Sientra’s AlloX2’s Unique Value in Managing Seroma and Infection Post Reconstruction Procedures
2021-08-10 20:01 ET
Sientra Reports Record Breast Products Revenue for Second Quarter 2021, Raises Revenue Guidance for Full Year 2021
2021-07-27 20:01 ET
Sientra to Report Second Quarter 2021 Financial Results on Tuesday, August 10, 2021
2021-07-19 12:00 ET
Sientra Appoints Two Medical Aesthetics Leaders to its Board of Directors
2021-07-12 12:00 ET
Sientra Announces Appointment of Chief Financial Officer
2021-06-11 12:00 ET
Sientra Announces Closing of Previously Announced Sale of miraDry Business to 1315 Capital
2021-06-01 20:01 ET
Sientra Announces Addition of Vice President of Research & Development
2021-05-18 20:05 ET
Sientra to Participate in Upcoming Virtual Investor Conferences
2021-05-11 20:05 ET
Sientra Reports Record First Quarter 2021 Financial Results
2021-05-11 20:01 ET
Sientra Announces Sale of miraDry Business to 1315 Capital
2021-05-05 12:00 ET
Sientra Receives Innovative Technology Contract from Vizient for AlloX2® Tissue Expander
2021-04-30 12:00 ET
Sientra and Butterfly Network Announce Strategic Partnership to Improve Diagnostic Surveillance of Breast Implant Patients
2021-04-27 20:05 ET
Sientra to Report First Quarter 2021 Financial Results on May 11, 2021
2021-03-11 21:05 ET
Sientra Reports Fourth Quarter and Full Year 2020 Financial Results
2021-03-11 21:01 ET
Sientra Announces Departure of CFO and Appointment of Interim CFO
2021-02-25 21:01 ET
Sientra to Report Fourth Quarter and Full Year 2020 Financial Results on March 11, 2021
2021-02-11 21:01 ET
Sientra to Present at the SVB Leerink 10th Annual Global Healthcare Conference
2021-02-09 02:30 ET
Sientra Announces Pricing of Public Offering of Common Stock
2021-02-08 21:01 ET
Sientra Commences Public Offering of Common Stock
2021-02-04 21:01 ET
Sientra Reports Preliminary Fourth Quarter and Full Year 2020 Results
2020-12-08 17:14 ET
Modulim Announces Seasoned Medical Device Executive Charles Huiner as Chief Executive Officer
2020-11-09 21:05 ET
Sientra Reports Third Quarter 2020 Financial Results
2020-11-09 21:01 ET
Sientra Appoints Ron Menezes as President and Chief Executive Officer
2020-11-06 13:30 ET
Sientra to Participate in Upcoming Virtual Investor Conferences
2020-10-20 20:01 ET
Sientra to Report Third Quarter 2020 Financial Results on November 9, 2020
2020-08-25 12:00 ET
Sientra Receives Regulatory Approval to Market OPUS® Breast Implants in Japan
2020-08-10 20:01 ET
Sientra Reports Second Quarter 2020 Financial Results
2020-07-29 20:01 ET
Sientra to Present at the Canaccord 40th Annual Growth Conference
2020-07-27 20:01 ET
Sientra to Report Second Quarter 2020 Financial Results on August 10, 2020
2020-07-14 20:01 ET
Sientra to Participate in COVID-19 Webinar Panel Hosted by Maxim Group
2020-06-02 20:01 ET
Sientra to Present at the William Blair 40th Annual Growth Stock Conference
2020-05-11 20:01 ET
Sientra Reports First Quarter 2020 Financial Results
2020-05-04 20:05 ET
Sientra to Report First Quarter 2020 Financial Results on May 11, 2020
2020-03-11 20:05 ET
Sientra Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-11 20:01 ET
Sientra Announces $60 Million Convertible Notes Investment from Deerfield Management
2020-02-26 21:05 ET
Sientra to Report 4Q19 Financial Results on March 11, 2020
2020-02-20 22:52 ET
Sientra to Present at the 9th Annual SVB Leerink Global Healthcare Conference
2020-02-19 22:00 ET
Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2020-01-13 12:00 ET
Sientra Announces Preliminary Unaudited 4Q19 Net Sales and Appointment of Caroline Van Hove to Board of Directors
2019-12-16 21:05 ET
Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2019-11-07 21:07 ET
Sientra Reports Third Quarter 2019 Financial Results
2019-11-07 21:01 ET
Sientra Announces Acquisition of the Independently Operated OPUS® Breast Implant Manufacturing Operation from Lubrizol Life Science
2019-10-31 20:30 ET
Sientra to Participate in Upcoming Investor Conferences
2019-10-17 20:05 ET
Sientra to Report Third Quarter 2019 Financial Results on November 7, 2019
2019-09-17 20:05 ET
Sientra Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2019-06-21 17:30 ET
Bowes Dermatology by Riverchase is One of First Locations to Offer New miraDry
2019-04-18 20:15 ET
Sientra to Release First Quarter Financial Results on May 8, 2019
2019-03-20 20:26 ET
Sientra® Issues Statement in Response to FDA Post-Approval Study Warning Letter
2019-03-12 20:01 ET
Sientra Reports Fourth Quarter and Full Year 2018 Financial Results
2019-03-04 21:44 ET
Sientra® to Release Fourth Quarter and Full Year 2018 Financial Results on March 12, 2019
2019-02-19 21:01 ET
Sientra to Present at the 8th Annual SVB Leerink Global Healthcare Conference
2019-01-04 12:00 ET
GC Aesthetics Announces Progress in U.S. Regulatory Strategy and Key Hires to Support Growth

SEC forms

Show financial reports only

SEC form 10
2023-11-13 00:00 ET
Sientra published news for 2023 q3
SEC form 8
2023-11-09 00:00 ET
Sientra reported for 2023 q3
SEC form 10
2023-08-11 00:00 ET
Sientra published news for 2023 q2
SEC form 8
2023-08-10 00:00 ET
Sientra reported for 2023 q2
SEC form 10
2023-05-15 00:00 ET
Sientra published news for 2023 q1
SEC form 6
2023-05-11 16:21 ET
Sientra published news for 2023 q1
SEC form 8
2023-05-11 00:00 ET
Sientra published news for 2023 q1
SEC form 6
2023-04-28 21:35 ET
Sientra published news for 2023 q1
SEC form 10
2023-04-18 00:00 ET
Sientra published news for 2022 q4
SEC form 10
2023-04-17 17:35 ET
Sientra published news for 2022 q4
SEC form 6
2023-03-31 17:09 ET
Sientra published news for 2022 q4
SEC form 6
2023-03-30 16:21 ET
Sientra published news for 2022 q4
SEC form 8
2023-03-30 00:00 ET
Sientra reported for 2022 q4
SEC form 6
2023-01-19 16:10 ET
Sientra published news for 2022 q4
SEC form 6
2022-12-20 06:08 ET
Sientra published news for 2022 q3
SEC form 6
2022-11-29 16:39 ET
Sientra published news for 2022 q3
SEC form 6
2022-11-17 17:23 ET
Sientra published news for 2022 q3
SEC form 10
2022-11-14 17:21 ET
Sientra reported for 2022 q3
SEC form 10
2022-11-14 00:00 ET
Sientra reported for 2022 q3
SEC form 6
2022-11-10 16:08 ET
Sientra published news for 2022 q3
SEC form 8
2022-11-10 00:00 ET
Sientra reported for 2022 q3
SEC form 6
2022-10-27 16:28 ET
Sientra published news for 2022 q3
SEC form 6
2022-10-20 06:04 ET
Sientra published news for 2022 q3
SEC form 6
2022-10-12 09:06 ET
Sientra published news for 2022 q3
SEC form 6
2022-10-11 06:32 ET
Sientra published news for 2022 q3
SEC form 6
2022-10-05 17:15 ET
Sientra published news for 2022 q3
SEC form 10
2022-08-11 16:17 ET
Sientra reported for 2022 q2
SEC form 6
2022-08-11 16:07 ET
Sientra published news for 2022 q2
SEC form 10
2022-08-11 00:00 ET
Sientra reported for 2022 q2
SEC form 8
2022-08-11 00:00 ET
Sientra reported for 2022 q2
SEC form 6
2022-06-15 06:07 ET
Sientra published news for 2022 q1
SEC form 6
2022-06-14 16:05 ET
Sientra published news for 2022 q1
SEC form 10
2022-05-12 16:17 ET
Sientra reported for 2022 q1
SEC form 6
2022-05-12 16:09 ET
Sientra published news for 2022 q1
SEC form 10
2022-05-12 00:00 ET
Sientra reported for 2022 q1
SEC form 8
2022-05-12 00:00 ET
Sientra reported for 2022 q1
SEC form 6
2022-04-28 18:10 ET
Sientra published news for 2022 q1
SEC form 10
2022-03-31 16:49 ET
Sientra published news for 2021 q4
SEC form 10
2022-03-31 00:00 ET
Sientra published news for 2021 q4
SEC form 6
2022-03-24 20:56 ET
Sientra published news for 2021 q4
SEC form 6
2022-03-23 16:37 ET
Sientra published news for 2021 q4
SEC form 8
2022-03-23 00:00 ET
Sientra published news for 2021 q4
SEC form 6
2022-01-10 09:02 ET
Sientra published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Sientra published news for 2021 q4
SEC form 6
2022-01-05 08:05 ET
Sientra published news for 2021 q4
SEC form 10
2021-11-12 16:17 ET
Sientra published news for 2021 q3
SEC form 10
2021-11-12 00:00 ET
Sientra published news for 2021 q3
SEC form 6
2021-11-10 16:30 ET
Sientra published news for 2021 q3
SEC form 8
2021-11-10 00:00 ET
Sientra published news for 2021 q3
SEC form 6
2021-10-04 06:06 ET
Sientra published news for 2021 q3
SEC form 6
2021-09-08 13:27 ET
Sientra published news for 2021 q2
SEC form 10
2021-08-10 16:16 ET
Sientra published news for 2021 q2
SEC form 6
2021-08-10 16:06 ET
Sientra published news for 2021 q2
SEC form 10
2021-08-10 00:00 ET
Sientra published news for 2021 q2
SEC form 8
2021-08-10 00:00 ET
Sientra published news for 2021 q2
SEC form 6
2021-07-22 17:22 ET
Sientra published news for 2021 q2
SEC form 6
2021-07-12 19:22 ET
Sientra published news for 2021 q2
SEC form 6
2021-06-16 16:01 ET
Sientra published news for 2021 q1
SEC form 6
2021-06-14 16:15 ET
Sientra published news for 2021 q1
SEC form 6
2021-05-11 16:47 ET
Sientra published news for 2021 q1
SEC form 10
2021-05-11 16:20 ET
Sientra published news for 2021 q1
SEC form 6
2021-05-11 16:10 ET
Sientra published news for 2021 q1
SEC form 10
2021-05-11 00:00 ET
Sientra published news for 2021 q1
SEC form 8
2021-05-11 00:00 ET
Sientra published news for 2021 q1
SEC form 6
2021-04-28 06:06 ET
Sientra published news for 2021 q1
SEC form 10
2021-03-11 16:16 ET
Sientra published news for 2020 q4
SEC form 6
2021-03-11 16:16 ET
Sientra published news for 2020 q4
SEC form 6
2021-03-11 16:06 ET
Sientra published news for 2020 q4
SEC form 6
2021-02-09 16:05 ET
Sientra published news for 2020 q4
SEC form 6
2021-02-08 06:09 ET
Sientra published news for 2020 q4
SEC form 6
2021-02-04 16:59 ET
Sientra published news for 2020 q4
SEC form 6
2020-11-10 21:47 ET
Sientra published news for 2020 q3
SEC form 10
2020-11-09 16:16 ET
Sientra published news for 2020 q3
SEC form 6
2020-11-09 16:10 ET
Sientra published news for 2020 q3